Masthead
About Thymosin Alpha-1 Source
An independent reading desk for the immune-peptide literature — forward-looking, evidence-graded, and honest about the gaps.
What this site is
Thymosin Alpha-1 Source is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on Thymosin Alpha-1. We read the science forward — surfacing what the trials established and where the field may be heading — while grading the evidence honestly, which means giving the null phase-3 sepsis result the same prominence as the encouraging hepatitis data. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
What "Source" means here
The word "source" in our name is editorial framing, not a commercial claim. We are a source of summaries and citations — a place to read the literature, not a place to obtain the peptide. We do not sell Thymosin Alpha-1, do not link to vendors, and take no position on where anyone might acquire research material. The name describes the position we occupy relative to the published record: a sourcing point for the science, not the substance.
How we work
Every quantitative statement on this site maps to a numbered citation in our Thymosin Alpha-1 references, drawn from PubMed, primary journals, and regulatory documents. We describe research findings in the third person and attribute them to their studies; we do not recommend doses, do not give treatment instructions, and do not phrase community anecdotes as proven outcomes. Reported real-world impressions are clearly labeled as anecdote and kept separate from cited findings. When the strongest trial is null, we say so plainly — that honesty is the point of the project.
What we are careful about
We keep Thymosin Alpha-1 distinct from the molecules it is routinely confused with — thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha — because conflation is the single biggest source of misinformation about this compound. We use only generic, scientific names. We note clearly that the peptide is not FDA-approved in the United States. And we frame it accurately as an immune modulator, never as an anabolic, growth, or performance compound.